List of Excipients in Branded Drug DIFLUPREDNATE OPHTHALMIC EMULSION

« Back to Dashboard

Generic Drugs Containing DIFLUPREDNATE OPHTHALMIC EMULSION

Company	Ingredient	NDC	Excipient
Dr Reddy's Laboratories Inc	difluprednate ophthalmic	43598-588	BORIC ACID
Dr Reddy's Laboratories Inc	difluprednate ophthalmic	43598-588	CASTOR OIL
Dr Reddy's Laboratories Inc	difluprednate ophthalmic	43598-588	EDETATE DISODIUM
Dr Reddy's Laboratories Inc	difluprednate ophthalmic	43598-588	GLYCERIN
Dr Reddy's Laboratories Inc	difluprednate ophthalmic	43598-588	POLYSORBATE 80

What are the Most Frequently-Used Excipients in DIFLUPREDNATE OPHTHALMIC EMULSION?

# Of NDCs	Excipient
1	BORIC ACID
1	CASTOR OIL
1	EDETATE DISODIUM
1	GLYCERIN
1	POLYSORBATE 80

Difluprednate Ophthalmic Emulsion Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Difluprednate ophthalmic emulsion is a small-molecule corticosteroid product whose commercial value depends on emulsion stability, ocular tolerability, sterile multidose delivery, and regulatory similarity to the reference product. The reference product, Durezol 0.05%, contains difluprednate in an emulsion with castor oil, polysorbate 80, boric acid, sodium borate, sodium edetate, sodium hydroxide, and water for injection. It is indicated for postoperative ocular inflammation and pain and for endogenous anterior uveitis.[1]

The most attractive excipient opportunities are not simple substitution of inactive ingredients. They are differentiated delivery systems, preservative-free multidose packaging, improved physical stability, lower irritation, manufacturing simplification, and formulations that support longer treatment courses or difficult-to-treat anterior-segment inflammation.

What excipients are used in difluprednate ophthalmic emulsion?

The Durezol formulation uses an oil-in-water emulsion. Castor oil is the principal oily phase, polysorbate 80 supports emulsification, borate components provide buffering, sodium edetate acts as a chelating agent, and sodium hydroxide adjusts pH.[1]

Excipient	Primary formulation function	Strategic relevance
Castor oil	Oil phase and vehicle for the lipophilic drug	Affects drug solubilization, droplet size, ocular residence, and tolerability
Polysorbate 80	Surfactant and emulsifier	Controls emulsion formation but can be sensitive to oxidation and degradation
Boric acid	Buffer component and tonicity contribution	Supports pH control and ocular comfort
Sodium borate decahydrate	Buffer component	Helps maintain formulation pH during storage
Sodium edetate	Chelating agent	Reduces metal-catalyzed oxidation and can support preservative or stability performance
Sodium hydroxide	pH adjustment	Controls drug stability, comfort, and emulsion behavior
Water for injection	Aqueous continuous phase	Must meet sterile ophthalmic quality requirements

The commercial formulation has a near-neutral pH and is supplied as a sterile ophthalmic emulsion in a multidose bottle. The label instructs patients to shake the bottle before use, reflecting the importance of redispersibility and dose uniformity.[1]

Why is an emulsion used for difluprednate?

Difluprednate is highly lipophilic. An emulsion can improve dispersion of the active ingredient in an aqueous ophthalmic vehicle while supporting delivery to the corneal and anterior-segment tissues.

An emulsion also creates formulation risks:

• Phase separation during storage
• Droplet-size growth or coalescence
• Variable dosing after insufficient shaking
• Surfactant degradation
• Drug migration between the oil and aqueous phases
• Ocular irritation from surfactant, oil, pH, or osmolality changes
• Container interaction and adsorption

A generic or reformulated product must therefore demonstrate more than chemical assay. The critical quality profile includes appearance, particle or droplet-size distribution, pH, osmolality, viscosity, redispersibility, assay, degradation products, microbial quality, sterility, and delivered-dose uniformity.

What excipient strategies can differentiate difluprednate products?

1. Optimize the oil phase

Castor oil is the reference oil phase and creates a direct benchmark for generic development. Alternative oils could include medium-chain triglycerides, mineral-oil systems, or other pharmaceutically acceptable lipid vehicles. Each alternative creates regulatory and technical tradeoffs.

A replacement oil may offer:

• Lower viscosity
• Improved ocular comfort
• Better oxidative stability
• More consistent droplet size
• Easier sterile filtration or aseptic processing
• Reduced dependency on a single excipient supplier

The main constraint is bioequivalence and product comparability. Changing the oil phase can change drug partitioning, release, corneal residence, and clinical performance. A formulation that is chemically equivalent but has materially different emulsion behavior may require more extensive comparative evidence.

2. Reduce surfactant-related irritation

Polysorbate 80 is widely used in ophthalmic products, but its concentration and degradation profile affect tolerability and stability. A developer could investigate lower surfactant loading, mixed surfactant systems, or nonionic surfactants with improved oxidative stability.

The commercial objective is not simply to eliminate polysorbate 80. It is to maintain:

• Small and stable droplets
• Rapid redispersion
• Uniform dose delivery
• Low ocular irritation
• Acceptable extractables and leachables
• Long shelf life

Surfactant reduction is most commercially relevant when it produces a clinically meaningful tolerability advantage or simplifies manufacturing.

3. Develop a preservative-free multidose system

Durezol is supplied in a multidose bottle without a conventional antimicrobial preservative listed among the inactive ingredients.[1] This creates an opportunity for packaging-led differentiation rather than excipient-led differentiation.

Potential systems include:

• One-way valve multidose containers
• Airless pump systems
• Metered-dose ophthalmic dispensers
• Unit-dose packaging
• Blow-fill-seal containers
• Sterile barrier systems with controlled microbial ingress

A preservative-free multidose product may appeal to patients with ocular-surface disease, repeated postoperative use, or sensitivity to preservatives. The regulatory burden shifts toward container-closure integrity, microbial ingress testing, dose reproducibility, and in-use stability.

4. Improve physical stability and shake robustness

The label's shake instruction creates a practical product-development target. A differentiated formulation could reduce the time or intensity of shaking needed to restore uniformity.

Useful formulation levers include:

• Narrower droplet-size distribution
• Optimized surfactant-to-oil ratio
• Improved density matching between phases
• Controlled viscosity
• Polymer or colloidal stabilizers
• Better bottle geometry
• Agitation-resistant suspension or emulsion design

Any strategy that reduces dose variability after storage or transport may have commercial value. The claim must be supported by reproducible dose-delivery testing across bottle orientation, storage conditions, and use intervals.

What patents protect difluprednate ophthalmic emulsion?

Difluprednate is a small molecule, so patent risk is concentrated in compound, formulation, manufacturing, and method-of-use rights rather than biosimilar exclusivity.

Relevant patent categories include:

Patent category	Potential subject matter	Commercial significance
Compound patents	Difluorinated corticosteroid structure and derivatives	Usually the earliest and broadest chemical protection
Formulation patents	Oil-in-water emulsions, surfactant systems, pH, droplet size, and stabilizers	May affect generic or reformulated product design
Method-of-use patents	Postoperative inflammation, pain, uveitis, dosing frequency, or treatment duration	Relevant to skinny-label and induced-infringement analysis
Manufacturing patents	Emulsification, sterilization, filling, and control of particle or droplet size	Can create process barriers even after composition patents expire
Packaging patents	Preservative-free multidose delivery and microbial-control systems	Important for differentiated follow-on products

The reference product is Durezol, NDA 021402. Current Orange Book patent and exclusivity information must be evaluated against the live FDA listing, because listed patents, delisting events, pediatric exclusivity, and expiration dates can change.[2]

A product developer should separate three questions:

1. Which patents remain listed for the reference NDA?
2. Which claims cover the proposed formulation or use?
3. Which claims are enforceable against the proposed label and manufacturing process?

A formulation that avoids the listed composition claims can still face method-of-use exposure if its label includes a patented indication or dosing regimen.

When does difluprednate lose exclusivity?

Difluprednate does not have biosimilar exclusivity because it is not a biologic. Generic applicants use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The relevant exclusivity framework is:

Exclusivity issue	Relevance to difluprednate
New chemical entity exclusivity	Applied to the original active ingredient if statutory criteria were met
Five-year NCE period	Blocks ordinary ANDA filing for the applicable period, subject to Paragraph IV timing rules
Three-year clinical-investigation exclusivity	May protect a new formulation, indication, or dosage form supported by required clinical studies
Pediatric exclusivity	Can add six months to certain listed exclusivities or patent terms
Patent term	Depends on the issued patent, regulatory review period, and terminal disclaimers
Orphan exclusivity	Generally not central to the broad commercial ophthalmic product
Biosimilar exclusivity	Not applicable

FDA's Orange Book identifies approved products, therapeutic equivalence ratings, listed patents, and certain exclusivity information.[2] FDA's ANDA and patent-certification rules determine how applicants address listed patents through Paragraph IV certifications, section viii statements, or Paragraph III certifications.[3]

Are Paragraph IV challenges and generic entry risks material?

Yes. Generic entry risk is generally higher for a conventional small-molecule ophthalmic product than for a biologic, but ophthalmic emulsions can present more complex development issues than simple aqueous solutions.

A Paragraph IV challenger may argue that a listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor may file patent litigation within the statutory period, potentially triggering a 30-month stay of approval under applicable circumstances.[3]

The principal generic entry risks are:

• Formulation patents covering the emulsion or excipient ratios
• Method-of-use patents covering uveitis or postoperative treatment
• Difficulty demonstrating equivalent emulsion performance
• Container-closure differences affecting preservative-free status
• Incomplete characterization of droplet-size distribution
• Litigation over label language
• Manufacturing patents covering sterile emulsification or filling

For a generic developer, a formulation that uses the same inactive ingredients may simplify product development but increase claim-overlap risk. A substantially different formulation may reduce patent overlap but increase bioequivalence, stability, and clinical comparability risk.

What FDA regulatory pathway applies to difluprednate ophthalmic emulsion?

A conventional generic product generally follows the ANDA pathway. FDA evaluates pharmaceutical equivalence, bioequivalence, quality, labeling, and manufacturing controls. Ophthalmic products must meet sterile-product requirements and demonstrate suitable control of particulate matter, sterility, container closure, and microbial quality.[4]

The principal regulatory strategy depends on the degree of formulation similarity:

Development strategy	Likely commercial advantage	Main regulatory burden
Same active and same excipients	Lower formulation risk and easier reference matching	Greater patent and supply-chain overlap
Same excipients with adjusted levels	Potential stability or tolerability benefit	Requires robust comparability data
New oil or surfactant system	Differentiation and possible patent clearance	Higher product-performance and equivalence risk
Preservative-free multidose device	Patient and prescriber differentiation	Device, microbial-ingress, and in-use stability data
Unit-dose emulsion	Strong sterility and preservative-free positioning	Higher packaging and cost of goods
Novel drug-delivery system	Potential premium pricing	May require a 505(b)(2) pathway rather than a standard ANDA

A 505(b)(2) application may be commercially attractive when the product uses a materially different formulation, delivery device, concentration, or dosing profile that cannot be supported through ordinary ANDA equivalence.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are not the availability of difluprednate alone. They are control of the emulsion and sterile filling process.

Key process controls include:

• Order of addition
• Mixing energy and shear
• Temperature control
• Hydration and dissolution of buffer components
• Surfactant dispersion
• Droplet-size reduction
• Homogenization endpoint
• Aseptic processing or sterilization approach
• Filling accuracy
• Container-closure integrity

Potential IP barriers may arise from claims directed to homogenization conditions, droplet-size ranges, phase composition, or preservative-free packaging. Freedom-to-operate analysis should cover the formulation, process, device, label, and manufacturing site.

What commercial opportunities exist in the difluprednate market?

Generic substitution

The largest near-term opportunity is a conventional generic with competitive pricing, reliable supply, and equivalent clinical positioning. Difluprednate can compete against prednisolone acetate and other topical corticosteroids where prescribers value potency, dosing convenience, or the emulsion format.

Premium preservative-free products

A preservative-free multidose product could target postoperative patients with ocular-surface sensitivity and chronic or recurrent inflammatory conditions. The premium must justify higher packaging and manufacturing costs.

Differentiated uveitis treatment

Endogenous anterior uveitis may support a product strategy focused on extended treatment, improved comfort, reduced dosing burden, or better adherence. Any promotional claim must remain consistent with the approved label or require regulatory approval.

Hospital and ambulatory surgery channels

Postoperative ophthalmic use creates an institutional and ambulatory surgery opportunity. Procurement decisions will emphasize acquisition cost, supply continuity, bottle usability, sterility assurance, and packaging waste.

Contract manufacturing and private-label supply

A manufacturer with validated sterile-emulsion capability can offer private-label or regional products. The strongest competitive position combines reliable sterile filling with a defensible container system and a cleared formulation design.

How does difluprednate compare with prednisolone acetate?

Attribute	Difluprednate ophthalmic emulsion	Prednisolone acetate ophthalmic suspension
Product type	Emulsion	Suspension
Active ingredient	Difluprednate 0.05%	Prednisolone acetate, commonly 1%
Shaking requirement	Yes	Yes
Primary commercial positioning	Potent corticosteroid for postoperative inflammation and anterior uveitis	Broadly used topical ophthalmic corticosteroid
Excipient opportunity	Oil phase, surfactant, preservative-free multidose delivery	Suspension particle control, settling, redispersion, and comfort
Generic complexity	Emulsion characterization and device compatibility	Suspension uniformity and particle-size control
Pricing potential	Often higher than older corticosteroid products	More mature generic pricing

Difluprednate's commercial opportunity depends on whether its formulation and dosing advantages support a price premium after generic competition. Excipient innovation must produce measurable improvements in stability, usability, comfort, or adherence.

What is the patent strength of a difluprednate follow-on product?

Patent strength is highest when claims cover the active ingredient and the proposed product necessarily practices those claims. It is lower when the follow-on product uses a different excipient system, different droplet-size profile, noninfringing manufacturing process, and a label that omits patented methods of use.

A practical strength assessment should score:

• Claim breadth
• Remaining patent term
• Orange Book listing status
• Patent-family continuity
• Validity exposure
• Enablement and written-description risk
• Prosecution-history estoppel
• Product claim overlap
• Method-of-use label exposure
• Probability of Paragraph IV litigation

Key Takeaways

• Durezol 0.05% is a sterile difluprednate oil-in-water ophthalmic emulsion.
• The reference excipient system uses castor oil, polysorbate 80, borate buffering, sodium edetate, sodium hydroxide, and water for injection.
• The strongest formulation opportunities involve emulsion stability, shake robustness, ocular comfort, and preservative-free multidose delivery.
• Difluprednate is a small molecule; biosimilar risk does not apply.
• Generic developers face formulation, method-of-use, manufacturing, packaging, and Orange Book patent risks.
• A conventional ANDA offers the lowest development burden, while a differentiated 505(b)(2) product offers greater commercial upside and higher regulatory risk.
• The most defensible product strategy combines a technically robust emulsion with a differentiated container system and a clean freedom-to-operate position.

FAQs About Difluprednate Ophthalmic Emulsion

Can castor oil be replaced in a difluprednate ophthalmic emulsion?

Yes, but replacement can change drug partitioning, emulsion stability, ocular tolerability, and bioequivalence. A new oil phase requires comparative formulation and performance evidence.

Is polysorbate 80 essential to difluprednate emulsion stability?

Not necessarily. It is used in the reference formulation, but alternative or mixed surfactant systems may be feasible if they maintain droplet stability, dose uniformity, sterility, and ocular tolerability.

Does difluprednate require a preservative?

The reference Durezol formulation does not list a conventional antimicrobial preservative among its inactive ingredients. Preservative-free status requires packaging and in-use microbial-control validation.

Is a difluprednate emulsion eligible for a standard ANDA?

A product that demonstrates pharmaceutical equivalence and bioequivalence to the reference product may be eligible for an ANDA. A materially different formulation or delivery system may require a 505(b)(2) application.

What is the largest commercial risk for a new difluprednate product?

For a conventional generic, the largest risks are price erosion, patent litigation, and manufacturing scale-up. For a differentiated product, the primary risks are clinical comparability, regulatory classification, packaging cost, and failure to establish a price premium.

References

1. U.S. Food and Drug Administration. (2023). Durezol (difluprednate ophthalmic emulsion) 0.05% prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Guidance for industry: Applications covered by section 505(b)(2).
4. U.S. Food and Drug Administration. (2004). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.
5. U.S. Pharmacopeia. (2024). General chapter <771> Ophthalmic products.